NEW YORK (GenomeWeb News) – Accelr8 Technology has established collaborations with a research institute and a hospital administration agency to conduct pre-clinical studies aimed at testing its clinical pathogen detection platform, the company said today.
Under the collaboration, Accelr8 will work with Washington University in St. Louis and the Denver Health and Hospital Authority to identify antibiotic resistance mechanisms using the firm’s BACcel system, and will target drug-resistant bacteria including methicillin-resistant Staphylococcus aureus, Pseudomonas, Acinetobacter, Klebsiella, E. coli, and other microbial pathogens that can cause hospital-acquired infections.
The research partners will provide “independent third-party assessments” of the BACcel tests, the company said.
“This plan will give us direct feedback from actual field experience as we integrate each additional test or engineering advance into the system,” Accelr8’s President David Howson said in a statement.
The initial phase of the collaborations will replicate previous studies on Accelr8’s rapid MRSA identification method. When these programs are completed, Accelr8 plans to extend these studies to include additional tests for bacteria and drug resistance.
The company said it already has used its methods in studies aimed at identifying other pathogens that are more difficult to identify and more deadly than MRSA.
Howson said the “relentless advance of antibiotic resistance will to some extent counterbalance improvements in preventive practices,” and that research programs such as Accelr8’s with Denver Health and Washington University “will ultimately prove the unique value of rapid, disease-directed diagnostics in reversing this deadly trend.”